Atea Pharmaceuticals, Inc. (AVIR) Q1 2025 Earnings
AVIR·Reported May 12, 2025·After market close
Diluted EPS came in at $-0.40 (+46.7% YoY), beat the $-0.56 consensus by $0.16.
Diluted EPS
$-0.40beat by $0.16
Consensus: $-0.56
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Atea Pharmaceuticals, Inc.'s Q1 2025 earnings report.
Atea Pharmaceuticals, Inc. (AVIR) reported Q1 2025 earnings on May 12, 2025 after market close.
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.40 for Q1 2025.
EPS beat the consensus estimate of $-0.56 by $0.16.
Compared to the same quarter a year prior, diluted EPS grew 46.7% from $-0.75.
You can read the 10-Q periodic report (0000950170-25-069367) directly on SEC EDGAR. The filing index links above go to sec.gov.